SAM
PTGX icon

Silvercrest Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Silvercrest Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.6M Sell
45,668
-2,263
-5% -$236K 0.04% 438
2026
Q1 		$5.05M Sell
47,931
-5,286
-10% -$468K 0.04% 428
2025
Q4 		$4.65M Hold
53,217
– – 0.03% 443
2025
Q3 		$3.54M Sell
53,217
-1,506
-3% -$85.6K 0.02% 470
2025
Q2 		$3.02M Hold
54,723
– – 0.02% 492
2025
Q1 		$2.65M Sell
54,723
-29,703
-35% -$1.24M 0.02% 503
2024
Q4 		$3.26M Sell
84,426
-828
-1% -$36.1K 0.02% 470
2024
Q3 		$3.84M Sell
85,254
-105,914
-55% -$4.28M 0.03% 410
2024
Q2 		$6.62M Buy
191,168
+2,425
+1% +$71K 0.05% 350
2024
Q1 		$5.46M Buy
188,743
+8,247
+5% +$224K 0.04% 377
2023
Q4 		$4.14M Buy
180,496
+34
+0% +$595 0.03% 403
2023
Q3 		$3.01M Buy
180,462
+52,265
+41% +$1.01M 0.02% 431
2023
Q2 		$3.54M Buy
128,197
+14,842
+13% +$371K 0.03% 417
2023
Q1 		$2.61M Sell
113,355
-127,390
-53% -$2.14M 0.02% 441
2022
Q4 		$2.63M Sell
240,745
-2,268
-0.9% -$19.1K 0.02% 431
2022
Q3 		$2.05M Buy
243,013
+128,254
+112% +$1.21M 0.02% 441
2022
Q2 		$908K Sell
114,759
-5,075
-4% -$61.4K 0.01% 580
2022
Q1 		$2.84M Buy
119,834
+1,119
+0.9% +$31.5K 0.02% 449
2021
Q4 		$4.06M Buy
118,715
+47,372
+66% +$1.5M 0.03% 411
2021
Q3 		$1.26M Sell
71,343
-48,048
-40% -$2.05M 0.01% 539
2021
Q2 		$5.36M Buy
+119,391
New +$3.94M 0.04% 379

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Silvercrest Asset Management's PTGX Position: Q2 2026 in Review

Silvercrest Asset Management reduced its Protagonist Therapeutics (PTGX) stake by 4.7% in Q2 2026, selling an estimated $236K and leaving 45,668 shares worth $5.6M. The position accounts for 0.04% of the portfolio, ranked #438.

Silvercrest Asset Management first reported a position in PTGX in Q2 2021 and has held it in 21 quarters since. The position peaked at $6.62M in Q2 2024. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Silvercrest Asset Management held 45,668 shares of Protagonist Therapeutics worth $5.6M as of Q2 2026.
  • Silvercrest Asset Management sold 2,263 Protagonist Therapeutics shares in Q2 2026, an estimated $236K.
  • Protagonist Therapeutics made up 0.04% of Silvercrest Asset Management's portfolio in Q2 2026, its #438 holding.
  • Silvercrest Asset Management first reported a position in Protagonist Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • Silvercrest Asset Management's Protagonist Therapeutics position peaked at $6.62M in Q2 2024.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Silvercrest Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.